Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
NT

NASDAQ · NTRA

Natera, Inc.

Healthcare · Medical - Diagnostics & Research

$400.71

Up+$9.92 (+2.54%)

Updated Oct 11, 2026, 12:35 PM

SID Score

7.3/10

Composite research score

Smart Money

62/100

Neutral

Market cap
31.89B
P/E ratio
-102.52
Dividend yield
0.00%
52-week range
$167.99 – $437.41
Volume
1.01M
Avg. volume
1.34M

Price performance · NTRA

NTRA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

NTRA closed at $400.71 after 20 trading sessions, up 17.24% for the selected period.

Last close
$400.71
Period change
+17.24%
Period low
$341.79
Period high
$425.64
Daily close
View OHLC price history
NTRA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$392.90$407.06$391.51$400.711.01M
Oct 8, 2026$387.59$392.955$380.39$390.792.44M
Oct 7, 2026$393.02$401.09$383.45$395.562.82M
Oct 6, 2026$429.01$437.4083$394.77$400.652.5M
Oct 5, 2026$410.32$427.18$405.24$425.642.02M
Oct 2, 2026$409.40$413.36$400.996$410.352.16M
Oct 1, 2026$413.31$423.4282$407.37$408.471.86M
Sep 30, 2026$416.02$427.4675$413.29$413.311.85M
Sep 29, 2026$413.69$421.64$409.25$414.522.06M
Sep 28, 2026$409.02$417.375$406.295$411.771.65M
Sep 25, 2026$410.00$415.75$407.475$412.561.61M
Sep 24, 2026$390.52$412.925$388.465$408.791.96M
Sep 23, 2026$386.94$394.86$384.96$390.791.69M
Sep 22, 2026$368.26$391.93$365.20$390.901.55M
Sep 21, 2026$371.92$373.07$363.96$370.641.98M
Sep 18, 2026$365.78$369.69$358.90$369.393.72M
Sep 17, 2026$350.50$366.70$348.26$366.312.56M
Sep 16, 2026$350.18$357.145$343.275$345.341.43M
Sep 15, 2026$340.34$351.7799$338.82$350.781.78M
Sep 14, 2026$327.91$343.00$327.1509$341.791.04M

Latest NTRA news

The latest Smart Investors Daily articles mentioning NTRA.

Stock researchCompany · Overview

NTRA research

Overview

Company profile and research snapshot.

Company profile

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$232.00
Implied upside
—
Analysts
27
NTRA recent ratings
DateFirmRatingTarget
Oct 7, 2026BarclaysOverweight—
Oct 6, 2026CitigroupBuy—
Oct 1, 2026GuggenheimBuy—
Sep 25, 2026RBC CapitalOutperform—
Sep 9, 2026UBSBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 10, 2026

Natera (NTRA) Could Be 33% Undervalued Following FDA Breakthrough Device Designation

Natera (NTRA) is back in focus after the US Food and Drug Administration granted Breakthrough Device designation to its multi cancer early detection blood test, a move that reshapes how investors frame the company’s diagnostics pipeline. The FDA news comes after a strong run in Natera’s share price. The 30-day share price return of 21.31% and the 90-day move of 48.44% have contributed to a year-to-date gain of 75.10%. The 1-year total shareholder return of 136.73% and the very large 3-year...

Yahoo · Oct 10, 2026

Why Natera (NTRA) Stock Is Up Today

Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 1.7% in the morning session after the U.S. Food and Drug Administration granted Breakthrough Device designation to its blood-based multi-cancer early detection assay.

Yahoo · Oct 9, 2026

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NASDAQ:NTRA) has received Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its investigational multi-cancer early detection (MCED) blood test, marking a regulatory milestone in the company’s efforts to develop screening technology capable of identifying multiple types of cancer. The Austin, Texas-based diagnostics company said the designation followed an FDA assessment of clinical performance data covering 12 cancer types, including the test’s sensitivit

Yahoo · Oct 9, 2026

FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay

AUSTIN, Texas, October 09, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By